select a format

Single User License
USD 2000 INR 130040
Site License
USD 4000 INR 260080
Corporate User License
USD 6000 INR 390120

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Graves Diseases-Pipeline Review, H2 2016

Graves Diseases-Pipeline Review, H2 2016


  • Products Id :- GMDHC8889IDB
  • |
  • Pages: 37
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Graves Diseases-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves Diseases-Pipeline Review, H2 2016, provides an overview of the Graves Diseases (Hormonal Disorders) pipeline landscape.

Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking and pregnancy. Treatment includes anti-thyroid medications, beta blockers and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves Diseases-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Graves Diseases (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves Diseases (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Graves Diseases and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2 and 1 respectively.

Graves Diseases (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Graves Diseases (Hormonal Disorders).

The pipeline guide reviews pipeline therapeutics for Graves Diseases (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Graves Diseases (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Graves Diseases (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Graves Diseases (Hormonal Disorders)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Graves Diseases (Hormonal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Graves Diseases (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Graves Diseases Overview 6

Therapeutics Development 7

Pipeline Products for Graves Diseases-Overview 7

Graves Diseases-Therapeutics under Development by Companies 8

Graves Diseases-Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Graves Diseases-Products under Development by Companies 11

Graves Diseases-Companies Involved in Therapeutics Development 12

Apitope International NV 12

Nova Therapeutics LLC 13

Novartis AG 14

Omeros Corp 15

Rodos BioTarget GmbH 16

Graves Diseases-Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

ATXGD-59-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

CFZ-533-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

K-170-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

NV-02-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Protein for Graves Diseases-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Small Molecule to Target GPR174 for Immunology, Neurology and Oncology-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Graves Diseases-Dormant Projects 33

Graves Diseases-Product Development Milestones 34

Featured News & Press Releases 34

Oct 26, 2016: Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves Disease 34

Jun 19, 2014: Apitope Progresses Graves' Disease Treatment 34

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Figures

Number of Products under Development for Graves Diseases, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Targets, H2 2016 18

Number of Products by Stage and Targets, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 24

List of Tables

Number of Products under Development for Graves Diseases, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Products under Development by Companies, H2 2016 11

Graves Diseases-Pipeline by Apitope International NV, H2 2016 12

Graves Diseases-Pipeline by Nova Therapeutics LLC, H2 2016 13

Graves Diseases-Pipeline by Novartis AG, H2 2016 14

Graves Diseases-Pipeline by Omeros Corp, H2 2016 15

Graves Diseases-Pipeline by Rodos BioTarget GmbH, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Graves Diseases-Dormant Projects, H2 2016 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Apitope International NV, Nova Therapeutics LLC, Novartis AG, Omeros Corp, Rodos BioTarget GmbH

Graves Diseases Therapeutic Products under Development, Key Players in Graves Diseases Therapeutics, Graves Diseases Pipeline Overview, Graves Diseases Pipeline, Graves Diseases Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com